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between December 1995 and February 1996. All of these patients had a primary diagnosis of LRTI, and were consecutively admitted to the Antrim Area Hospital from December 1995 to February 1996.
Study design
The study was a prospective, controlled clinical trial carried out at a single centre, the Antrim Area Hospital in Northern Ireland. All of the patients were followed over the duration of their complete hospital stay. The patients in the protocol group were also followed-up at 28 days to ensure that early discharge from hospital did not have a detrimental effect on their clinical outcome. No loss to follow-up was reported.
Analysis of effectiveness
All of the patients included in the study were accounted for in the analysis. The primary outcome measures were the duration of treatment in hospital (days), the length of hospital stay (days), the duration of i.v. antimicrobial treatment, and the treatment failure rate.
The authors reported that the two groups of patients were comparable. There was no significant difference in relation to the patients' living arrangements prior to hospital admission, their age, gender, mean onset of days of illness before admission, and disease severity.
A wide range of laboratory tests was conducted for the control and protocol patients. A higher proportion of patients had a sputum culture ordered in the protocol group (98.3%, 113 patients) than in the control group (54.5%, 61 patients), (p>0.05). The authors did not report whether these values were adjusted.
Effectiveness results
The study reported the geometric mean of the primary outcome measures for both the control and protocol groups. The mean length of stay in hospital was 9.2 days (range: 8.5 -10.0) in the control group and 4.5 days (range: 4.0 -5.1) in the protocol group. This produced a control-to-protocol ratio of 2.04 (95% confidence interval, CI: 1.75 -2.34; p<0.001).
The mean duration of i.v. antimicrobial treatment was 5.7 days (range: 5.2 -6.2) in the control group and 2.1 days (range: 1.8 -2.6) in the protocol group. This produced a control-to-protocol ratio of 2.71 (95% CI: 2.20 -3.22; p<0.001).
The mean duration of treatment in hospital was 8.8 days (range: 8.2 -9.4) in the control group and 4.5 days (range: 4.0 -5.0) in the protocol group. This produced a control-to-protocol ratio of 1.96 (95% CI: 1.69 -2.25; p<0.001).
The treatment failure rate was 31.3% (35 patients) in the control group and 7.8% (9 patients) in the protocol group, (p<0.001).
Clinical conclusions
The authors reported that the results demonstrated that the antimicrobial-prescribing protocol had a statistically significant impact in relation to the clinical outcome measures. The patients treated with the protocol had a significant reduction in the duration of hospital treatment, the length of hospital stay, and the duration of i.v. therapy. They also had a statistically significantly reduced chance of treatment failure when compared with the control group.
Measure of benefits used in the economic analysis
No summary measure of health benefit was used in the economic analysis, and the outcomes were left disaggregated. The analysis should therefore be considered as a cost-consequences analysis.
